Drug intelligence / Profile preview

PV-3212

Development stage: Preclinical
Lead developer: Provid Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Vaginal, Sublingual, Buccal, Transdermal, Intraperitoneal, Intra-arterial, Parenteral

Overview

PV-3212 is a novel, second-generation small molecule inhibitor developed by Provid Pharmaceuticals for the treatment of multiple sclerosis (MS). It specifically targets the MHC class II allele HLA-DRB1*15:01 (DR15), which is the primary genetic risk factor for MS. By inhibiting the presentation of autoantigens by DR15, PV-3212 aims to modulate the autoimmune response characteristic of the disease. The compound is designed for high metabolic stability and is currently in the IND-enabling stage of development.

Other names: Multiple Sclerosis Program

Targets

HLA-DRB5*01:01 (HLA class II histocompatibility antigen, DR beta 5 chain)HLA-DRB1*15:01

Beyond the preview

Go deeper on PV-3212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PV-3212.

Explore the full profile